Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Prime Medicine, Inc. (PRME) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.17, with a market capitalisation of $576.78M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.67 to $6.94. This page covers its latest market performance, valuation, price trends and company information.
$576.78M | |
$3.17 | |
$21.73 | |
$1.11 | |
$3.14 | |
44.00 | |
3.26M | |
-- | |
$6.94 | |
$2.67 | |
-- | |
-- |
Prime Medicine, Inc. (PRME) is trading at $3.17 in pre-market trading as of 2026-09-16 10:07:00, up 0.96% ($0.03) from the previous close of $3.14
Pre-market trading shows how investors are pricing PRME before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Prime Medicine, Inc. (PRME) moved from $3.70 to $3.17, representing a decline of 14.32% ($0.53).
The stock traded between $3.00 and $3.86 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.73 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 11.7%
PRME is currently trading at $3.17, placing it 11.7% of the way from its 52-week low of $2.67 to its 52-week high of $6.94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 146 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Prime Medicine, Inc. (PRME) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.